NASDAQ : JANX
Janux Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 17.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.09B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.07B |
| Enterprise Value | 118.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.14M |
| Shares Outstanding | 61.14M |
| Shares Change (YoY) | +6.20% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 5.92% |
| Owned by Institutions (%) | 77.13% |
| Float | 42.53M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.50 |
| Forward PS | 57.27 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.35 |
| Quick Ratio | 16.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -10.70% |
| Return on Assets (ROA) | -8.80% |
| Return on Invested Capital (ROIC) | -9.15% |
| Return on Capital Employed (ROCE) | -15.15% |
| Weighted Average Cost of Capital (WACC) | 17.06% |
| Revenue Per Employee | $212,389 |
| Profits Per Employee | -$907,894 |
| Employee Count | 113 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.39 |
| 52-Week Price Change | -37.18% |
| 50-Day Moving Average | 17.60 |
| 200-Day Moving Average | 15.33 |
| Relative Strength Index (RSI) | 51.87 |
| Average Volume (20 Days) | 775,737 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.33M |
| Short Previous Month | 5.68M |
| Short % of Shares Out | 8.71% |
| Short % of Float | 12.53% |
| Short Ratio (days to cover) | 5.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 24.00M |
| Gross Profit | -99.98M |
| Operating Income | -143.56M |
| Pretax Income | -102.59M |
| Net Income | -102.59M |
| EBITDA | -141.65M |
| EBIT | -143.56M |
| Loss Per Share | -$1.64 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 970.91M |
| Total Debt | 20.99M |
| Net Cash | 949.92M |
| Net Cash Per Share | $15.54 |
| Equity (Book Value) | 927.98M |
| Book Value Per Share | 15.19 |
| Working Capital | 923.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -41.25M |
| Capital Expenditures | -674,000 |
| Depreciation & Amortization | 1.90M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.93M |
| FCF Per Share | -$0.69 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -598.15% |
| Pretax Margin | -427.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.20% |
| Shareholder Yield | -6.20% |
| Earnings Yield | -9.40% |
| FCF Yield | -3.93% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.81 |
| Price Target Difference | 93.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | -5.28% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 8.77 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |